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Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping
for targeted prophylaxis cost-effective in the Turkish population?
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Background/aim: The aim of this study was to assess unnecessary immunization rates and compare the cost-effectiveness of targeted
prophylaxis with fetal Rh genotyping with that of traditional management of Rh-Rh incompatibility in a virtual economic model.
Materials and methods: This retrospective data analysis was conducted at two tertiary centers between 2011 and 2015. The data of 1135
pregnant women were analyzed. The main outcome measure was to determine the unnecessary immunization rate among the whole
Rh-Rh incompatibility group. The second outcome measure was to compare the cost-effectiveness of universal immunization with that
of targeted prophylaxis with fetal Rh genotyping in a virtual economic model.
Results: Average cost per patient was found as $259.20 with universal prophylaxis and the total cost was $177,344, whereas if targeted
prophylaxis had been applied to these patients the total cost would have been $263,392 and cost per patient would have been $385.
Universal prophylaxis was more cost-effective than targeted prophylaxis in terms of both total cost and cost per patient (P < 0.0001).
Conclusion: Unless the cost of noninvasive fetal Rh genotyping is reduced, a universal approach of anti-D immune globulin prophylaxis
is more cost-effective than noninvasive determination of fetal Rh genotyping with targeted prophylaxis.
Key words: Anti-D prophylaxis, cell-free DNA, cost-effectiveness, noninvasive, Rh genotyping

1. Introduction
Rh-Rh alloimmunization is a potential result of
fetomaternal hemorrhage, which occurs during childbirth
or during pregnancy in Rh-negative women who have
an Rh-positive fetus. If a sufficient volume of fetal RhDpositive blood enters the maternal circulation, the mother
will be sensitized and hemolytic disease of the fetus
or newborn may occur. The severity of the disease is
variable and it may result in fetal hydrops, fetal anemia,
developmental problems, and even intrauterine death (1).
Since the 1960s, routine antenatal prophylaxis with
anti-RhD immunoglobulin in the third trimester to
prevent rhesus sensitization for all RhD-negative pregnant
women, regardless of the rhesus status of the baby, has
been standard in many countries as recommended by
most clinical guidelines (1,2). Anti-RhD immunoglobulin
is given antenatally in the third trimester and repeated
postpartum prophylaxis within 72 h of delivery is
offered only to RhD-negative women who have given
birth to an RhD-positive baby (3). Routine antenatal
anti-D prophylaxis (RAADP) at the beginning of the
* Correspondence: sefakelekci@gmail.com

third trimester has been introduced in several countries,
reducing the incidence of RhD immunization to 0.2%–
0.3%. Unfortunately, there are also rare side effects of
this application and there are limited stocks of anti-D
immunoglobulin as well as other blood products.
After the identification of cell-free fetal DNA in the
blood of pregnant women, several institutes have provided
a fetal RhD genotyping service for RhD-negative women
with a measureable concentration of anti-RhD antibody
(3,4). Cell-free fetal DNA constitutes 3%–6% of the cellfree DNA in maternal serum (5). Cell-free fetal DNA from
maternal blood is tested for the presence or absence of the
RhD gene, and results are used to direct management of
the pregnancy. Several studies have confirmed the safety
and high diagnostic accuracy of this approach (6–10).
Fetal RhD genotyping was found to be sufficiently accurate
to be used from 11 weeks’ gestation (3).
In the NICE guidelines issued in 2008, a single dose
of anti-D immunoglobulin at 28 weeks was reported to be
suitable in terms of cost-effectiveness. However, RAADP
has often been administered to all RhD-negative pregnant

1

DEMİREL et al. / Turk J Med Sci
women, even though 40% will carry a compatible RhDnegative fetus and so are not at risk for RhD immunization
(2,3). RAADP treatment in such women unnecessarily
exposes them to a human plasma product and is wasteful
of the limited supply of anti-D immunoglobulin, which
should be given only when strictly indicated. This allows
administration of RAADP selectively to RhD-negative
women with an RhD-positive fetus and avoids giving it to
women who are not at risk (11).
The aim of this study is to estimate the incidence of
RhD-negative pregnant women who have given birth to
an RhD-negative baby with RAADP in the third trimester,
to assess unnecessary immunization rates, and to compare
the cost-effectiveness of fetal Rh genotyping with targeted
prophylaxis with that of traditional management of Rh-Rh
incompatibility in a mathematical model.
2. Material and methods
This retrospective data analysis was conducted at the İzmir
Kâtip Çelebi University and Giresun University Faculties
of Medicine, Department of Obstetrics and Gynecology,
between 2011 and 2015. After obtaining the approval of
the local institutional review boards (2015/), the data of
1135 pregnant women were analyzed.
A total 1135 pregnant women given RAADP were
included in this study. Out of those 1135 women, 132
pregnant women were excluded from data analysis due
to incomplete records and 319 were excluded from the
study because of early or late pregnancy losses, ectopic
pregnancy, or positive indirect Coombs test. Thus, the data
of a total of 684 pregnant women were analyzed.
Demographic data of pregnant women, number of
anti-D prophylaxis administrations, laboratory results, Rh
status of newborns, and cost per patient and total cost of
traditional management of Rh-Rh incompatibility were
recorded. Our main outcome measure was to determine
the unnecessary immunization rate and the percentage of
Rh-negative newborns with Rh-negative mothers among
the whole Rh-Rh incompatibility group. The second
outcome measure was to compare the cost-effectiveness of
universal immunization and that of targeted prophylaxis
with fetal Rh genotyping in a mathematical model.
In this economic model, if fetal Rh genotyping from
maternal blood were applied to all of the 684 patients
who received universal RAADP, the fetal Rh-negative
group would have been excluded from the universal
management group and would have been managed
without a need for antenatal prophylaxis. The pregnancies
having an Rh-positive fetus would have been monitored
with conventional methods. Costs of laboratory tests for
antenatal prophylaxis, costs of hospitalization and anti-D
for antenatal applications, and costs of laboratory tests for
fetal Rh genotyping in maternal blood were calculated in
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total and per patient in US dollars. The cost of conventional
prophylaxis was also calculated per patient and in total
in US dollars. These two management methods were
compared in terms of costs.
2.1. Statistical analysis
Data were analyzed using SPSS 22.0 for Windows (IBM
Corp., Armonk, NY, USA). Mean, median, standard
deviation, and ratio values were used in comparisons
of data. The chi-square test was used for analyses of
qualitative data. Differences were considered statistically
significant at P ≤ 0.05.
3. Results
A total of 1135 patients with Rh-Rh incompatibility were
included in the study from two different tertiary centers;
319 patients were excluded from the study due to early/late
pregnancy losses or a positive indirect Coombs test, while
132 patients were excluded due to incomplete records. A
total of 1304 anti-D globulin administrations were applied
to the 684 patients who were included in the study. Anti-D
was given once to 132 patients, twice to 484 patients, and
three times to 68 patients. The mean age of patients was
31.8 years and median gravida was three, while parity was
two and abortion was one. The incidence of Rh-negative
babies born to Rh-negative mothers was 22.2% (152/684)
and total pregnancy loss rate was 28.1% (319/1135).
Laboratory costs, the cost of visits, hospitalization
costs, and RAADP costs were calculated for universal
prophylaxis; the average cost per patient was found to
be $259.20 and total cost was $177,344. With this type of
management, the cost per patient was $153.80 for patients
having an Rh-negative baby and the total cost was $23,392.
However, the cost per patient was $289.30 for patients
having an Rh-positive baby and total cost was $153,952 for
pregnant women having an Rh-positive fetus.
If targeted prophylaxis had been applied to these
patients with the use of Rh genotyping from maternal
blood, with the inclusion of all other costs, total cost would
have been $263,392 and cost per patient would have been
$385. Cost per patient would have been $160 for patients
having an Rh-negative fetus and cost per patient would
have been $449.30 for patients having an Rh-positive fetus,
with a total cost of $239,027.
Comparisons of universal and targeted management
costs are given in the Table. Universal prophylaxis was
more cost-effective than traditional prophylaxis in terms
of both total and per-patient costs (P < 0.0001). However,
in subgroup analyses, the Rh-negative subgroups were
similar in terms of cost-effectiveness between universal and
targeted prophylaxis (P = 0.88), but universal prophylaxis
was found as more cost-effective than targeted prophylaxis
in the Rh-positive subgroup (P = 0.0016).
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Table. Comparison of cost-effectiveness of noninvasive fetal Rh genotyping for targeted prophylaxis and traditional prophylaxis.
Total
(n = 684)
Groups

Rh-negative fetuses
(n = 152)

Rh-positive fetuses
(n = 532)

Traditional
management

Targeted
management

Traditional
management

Targeted
management

Traditional
management

Targeted
management

Cost per pregnancy (USD)

259.20

385

153.80

160

289.30

449.30

Total cost (USD)

177,344

263,392

23,392

24,320

153,952

239,027

P-value

<0.001

4. Discussion
This retrospective data analysis and virtual economic
model showed that noninvasive fetal Rh genotyping and
targeted prophylaxis does not seem cost-effective in the
Turkish population in today’s conditions when compared
to universal Rh prophylaxis. However, in subgroup analysis
of Rh-negative fetuses, targeted prophylaxis and universal
prophylaxis were comparable to each other.
In our study the rate of pregnancy loss was 28.1%. This
rate is higher than that expected in the general population
and this is due to the fact that our centers were tertiary
centers and the study group consisted of referred patients.
The incidence of Rh-negative babies born to Rh-negative
mothers was 22.2%. This rate was also high as it is reported
to be approximately 10%–15% in the Turkish population
in the literature (12). The explanation for this is that the
babies in our study all had Rh-negative mothers. The entire
population consists of both Rh-negative and Rh-positive
mothers and so the rate is lower. The presence of the Rh
antigen varies between races. A high frequency of Rhnegative genotype exceeding 0.50, as typically described
over several decades, is present in the Basque region
of France. This rate is 15% in Caucasians, 8% in Africa,
and about 1% in East Asia (13). Our higher rate could be
related to migration to our region from outside and also to
our hospital-based study. This cost-effectiveness study may
have more significant results if it is performed in countries
that have a higher incidence of the Rh-negative genotype.
In our study the average cost per pregnancy was found to
be $259.20 with universal prophylaxis. If we had managed
these patients selectively with the detection of fetal Rh
genotype prenatally, the cost would have been $449.30
per patient with that approach. Because Rh-negative
mothers carrying Rh-negative fetuses would not need
immunization, the cost of targeted management would
be $385. Fetal Rh genotyping with targeted prophylaxis
was not more cost-effective than universal prophylaxis
in our model. One study in the United States specifically
evaluated the cost-effectiveness of routine antenatal Rh IG
prophylaxis in D-negative women versus noninvasive fetal

0.88

0.0016

Rh genotyping with targeted prophylaxis. In this economic
model, the cost of routine prophylaxis was $351 per
pregnancy compared with $682 for noninvasive testing.
As approximately 60% of women tested would still require
administration of Rh IG, the cost of testing would have to
decrease to $119 to have a neutral economic impact (14).
A similar analysis was conducted in Quebec in 2013 with
similar results, indicating that routine prophylaxis is far
more cost-effective than noninvasive fetal Rh genotyping
followed by targeted prophylaxis (15). These findings were
similar to our results.
It should be kept in mind that anti-D immune
globulin products are produced from human plasma, so
theoretically they have a risk of transmission of infectious
agents. In 1978, one case of hepatitis C transmission was
reported in Ireland with the use of contaminated Rh IG
products (16). In the United States there is no reported case
of transmission by these products (17). All blood products
also have a risk of transmission of prion diseases. One
possible case of acquisition of Creutzfeldt–Jakob disease in
a patient from the United Kingdom who received clotting
factor concentrate has been reported (18). In addition to
these risks, the second drawback of universal prophylaxis
is the limitation of Rh immune globulins stocks due to it
being a human product.
The accuracy rates of detection of fetal Rh genotype
in maternal blood were reported as 98%–100% in many
recent studies (19,20). Cell-free fetal DNA constitutes
3%–6% of the cell-free DNA in maternal serum (5,21).
Fetal DNA can be obtained from maternal serum by the
fifth week of pregnancy with this method. Fetal RHD
genotyping was found to be sufficiently accurate to be used
from 11 weeks of gestation (3,19,20). Therefore, if targeted
screening becomes cost-effective with time, noninvasive
fetal Rh genotyping from maternal blood could be added
to screening at 11–13 weeks in obstetrics practice.
A limitation of our study may be the retrospective
nature and use of hospital-based data. Furthermore, this
study is a virtual economic model. We want to indicate
that our results only reflect the cost-effectiveness of
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applications in the health system of Turkey; the costs of
medications, laboratory tests, hospital visits, or genetic
tests may differ from country to country. However, our
study has several strengths, such as a large sample size and
a relatively homogeneous group of pregnant women.
In conclusion, unless the cost of noninvasive fetal Rh
genotyping is reduced over time, a universal approach

to anti-D immune globulin prophylaxis seems more
cost-effective than noninvasive determination of fetal
Rh genotyping followed by targeted prophylaxis. If this
expectation is realized, it will enable routine fetal RHD
genotyping to avoid unnecessary immunization of RhDnegative women carrying RhD-negative fetuses for ethical
and economic reasons.
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